Century Therapeutics downgraded by JP Morgan with a new price target

8/28/23 7:15:43 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

JP Morgan downgraded Century Therapeutics from Overweight to Neutral and set a new price target of $5.00 from $28.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IPSC

Date	Price Target	Rating	Analyst
8/8/2024	$6.00	Buy	Rodman & Renshaw
8/28/2023	$28.00 → $5.00	Overweight → Neutral	JP Morgan
12/27/2022	$19.00	Buy	Chardan Capital Markets
10/31/2022	$15.00	Buy	Guggenheim
10/10/2022	$28.00	Buy	Canaccord Genuity
5/23/2022	$27.00	Buy	H.C. Wainwright
5/12/2022		Mkt Perform	William Blair
11/19/2021	$33.00 → $32.00	Outperform	SVB Leerink